Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis

Clinical Infectious Diseases

Volumn 24, Issue 4, 1997, Pages 635-642

  White, Mary H ^a   Anaissie, Elias J ^b   Kusne, Shimon ^b   Wingard, John R ^b   Hiemenz, John W ^b   Cantor, Alan ^b   Gurwith, Marc ^b   Du Mond, Charles ^b   Mamelok, Richard D ^b   Bowden, Raleigh A ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLOSIS; CHILD; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS; CHILD; COLLOIDS; CONSUMER PRODUCT SAFETY; DRUG CARRIERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0030984333     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Weiland D, Ferguson RM, Peterson PK, Snover DC, Simmons RL, Najarian JS. Aspergillosis in 25 renal transplant patients. Epidemiology, clinical presentation, diagnosis, and management Ann Surg 1983;198:622-9.
2. Brin RH, Enzmann DR, Remington JS. Intracranial infection in cardiac transplant recipients. Ann Neurol 1981;9:107-19.
3. Wingard JR, Beals SU, Santos GW, Merz WG, Saral R. Aspergillus infections in bone marrow transplant recipients. Bone Marrow Transplant 1987;2:175-81.
4. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990;12:1147-201.
5. Bangham AD, Hill MW, Miller NGA. Preparation and use of liposomes as models of biological membranes. In: Korn ED, ed. Methods in membrane biology. Vol 1. New York: Plenum Press, 1974:1-68.
6. Guo LSS, Fielding RM, Mufson D. Pharmacokinetic study of a novel amphotericin B colloidal dispersion with improved therapeutic index. Ann N Y Acad Sci 1991;618:586-8.
7. Fielding RM, Smith PC, Wang LH, Porter J, Guo LSS. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother 1991;35:1208-13.
8. Oppenheim DA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995;21:1145-53.
9. Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik J. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996;173:1208-15.
10. Denning DW, Lee JY, Hostetler JS, et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994;97:135-44.
11. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
12. Burch PA, Karp JE, Merz WG, Kuhlman JE, Fishman EK. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol 1987;5:1985-93.